Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Acalabrutinib + CD19R(EQ)28zetaEGFRt+ Tn/mem cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Acalabrutinib||Calquence||ACP-196||BTK inhibitor 35||Calquence (acalabrutinib) selectively inhibits BTK, resulting in decreased B-cell receptor signaling, and potentially leading to decreased tumor cell proliferation (PMID: 27903679, PMID: 26957112). Calquence (acalabrutinib) is FDA approved for use in patients with mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma (FDA.gov).|
|CD19R(EQ)28zetaEGFRt+ Tn/mem cells||CD19R(EQ)28zeta/EGFRt-expressing naive and memory T cells||CD19R(EQ)28zetaEGFRt+ Tn/mem cells consist of a preparation of CD62L-positive naive and memory T-lymphocytes engineered to express a modified CD19-targeting (CD19R(EQ)) chimeric antigen receptor (CAR) as well as CD28 and CD3-zeta signaling domains, as well as a truncated EGFR (EGFRt), which potentially induces toxicity against tumor cells expressing CD19 (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04484012||Phase II||Acalabrutinib + CD19R(EQ)28zetaEGFRt+ Tn/mem cells||Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma||Recruiting||USA||0|